查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1212676

循環腫瘤細胞(CTC)診斷藥的全球市場

Circulating Tumor Cell (CTC) Diagnostics
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

循環腫瘤細胞(CTC)診斷藥的全球市場2030年將達到213億美元

在COVID-19後改變的商務環境中，2022年91億美元的循環腫瘤細胞(CTC)診斷藥的全球市場，在2030年前將達到213億美元的規模，分析期間的2022-2030年將以11.2％的年複合成長率增長。本報告所分析之市場區隔之一的檢測和濃縮年複合成長率將記錄10.8％，到分析期間結束時達到138億美元。考慮疫情後的復甦趨勢，分析領域今後8年的年複合成長率將修正為12.8％。

美國市場估算為27億美元，中國則將以年複合成長率10.3％增長

美國的循環腫瘤細胞(CTC)診斷藥市場在2022年估算為成為27億美元。作為世界第2大經濟大國的中國，在2022年～2030年年複合成長率預計將為10.3％，在2030年將達到36億美元的市場規模。其他熱門的地區市場有日本和加拿大，在2022年～2030年預計將各以10.2％和9.5％的速度成長。在歐洲市場中，德國將以年複合成長率7.9％成長。

調查對像企業範例

  • ApoCell, Inc.
  • Biocep Ltd.
  • Biocept, Inc.
  • Biofluidica Microtechnologies LLC
  • Celltraffix Inc.
  • Clearbridge Biomedics
  • Creatv Microtech, Inc.
  • Cynvenio Biosystems, Inc.
  • Fluxion Biosciences, Inc.
  • Ikonisys, Inc.
  • IVDiagnostics, Inc.
  • Janssen Diagnostics LLC
  • QIAGEN Hannover GmbH
  • Rarecells Sas
  • Screencell
  • Stemcell Technologies, Inc.

目錄

第1章 調查手法

第2章 摘要整理

  • 市場概要
  • 主要企業
  • 市場趨勢與推動因素
  • 全球市場預測

第3章 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲
  • 亞太地區
  • 全球其他地區

第4章 競爭

簡介目錄
Product Code: MCP-7869

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Circulating Tumor Cell (CTC) Diagnostics Market to Reach $21.3 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Circulating Tumor Cell (CTC) Diagnostics estimated at US$9.1 Billion in the year 2022, is projected to reach a revised size of US$21.3 Billion by 2030, growing at a CAGR of 11.2% over the analysis period 2022-2030. Detection & Enrichment, one of the segments analyzed in the report, is projected to record a 10.8% CAGR and reach US$13.8 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Analysis segment is readjusted to a revised 12.8% CAGR for the next 8-year period.

The U.S. Market is Estimated at $2.7 Billion, While China is Forecast to Grow at 10.3% CAGR

The Circulating Tumor Cell (CTC) Diagnostics market in the U.S. is estimated at US$2.7 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$3.6 Billion by the year 2030 trailing a CAGR of 10.3% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 10.2% and 9.5% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 7.9% CAGR.

Select Competitors (Total 48 Featured):

  • ApoCell, Inc.
  • Biocep Ltd.
  • Biocept, Inc.
  • Biofluidica Microtechnologies LLC
  • Celltraffix Inc.
  • Clearbridge Biomedics
  • Creatv Microtech, Inc.
  • Cynvenio Biosystems, Inc.
  • Fluxion Biosciences, Inc.
  • Ikonisys, Inc.
  • IVDiagnostics, Inc.
  • Janssen Diagnostics LLC
  • QIAGEN Hannover GmbH
  • Rarecells Sas
  • Screencell
  • Stemcell Technologies, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Market Outlook
    • Recent Market Activity
    • Clinical Relevance of CTCs
    • CTC Detection - Real-Time 'Liquid Biopsy' Scores Over Surgical Biopsy
    • Major Challenges in CTC Diagnostics
    • Need for CTC Enrichment and Popular Methods
    • CTC Enrichment Techniques
    • Select Available CTC Detection Technologies
    • Select CTC Isolation Systems - A Brief Comparison
    • CTC Identification - Various Approaches
    • CTC Identification Approaches
    • List of mRNA Markers for RT-PCR-based Detection of CTCs by Tumor Type
    • CellSearch System™ - The First FDA Approved Automated Enrichment/Isolation Technique
    • Rising Incidence of Cancer - An Opportunity Indicator
    • Cancer Prone Sites based on Age
    • Circulating Tumor Cell (CTC) Diagnostics - Global Key Competitors Percentage Market Share in 2022 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
    • ApoCell, Inc. (US)
    • Biocep Ltd. (Israel)
    • Biocept, Inc. (US)
    • Biofluidica Microtechnologies LLC (US)
    • Celltraffix Inc. (US)
    • Clearbridge Biomedics (Singapore)
    • Creatv Microtech, Inc. (US)
    • Cynvenio Biosystems, Inc. (US)
    • Epic Biosciences Inc. (US)
    • Fluxion Biosciences, Inc. (US)
    • Ikonisys, Inc. (US)
    • IVDiagnostics, Inc. (US)
    • Janssen Diagnostics LLC (US)
    • QIAGEN Hannover GmbH (Germany)
    • RARECELLS SAS (Italy)
    • ScreenCell (France)
    • STEMCELL Technologies, Inc. (Canada)
  • 3. MARKET TRENDS & DRIVERS
    • Liquid Biopsy - the New Buzzword in Healthcare
    • Select Companies Active in Cancer Liquid Biopsy
    • CTCs for Personalized Cancer Treatment
    • Microfluidic Chip-based Technologies - A Promising Avenue for Cancer Diagnosis
    • CTC Microdevices Hog the Limelight
    • Increasing Research Reveal Further Complexities to CTC Composition and Behavior
    • EpCAM Glycoprotein - Insufficient for CTC Detection
    • New Isolation Techniques Show Promise in Detecting EpCAM-Negative CTCs
    • Physical Property-based Enrichment Technologies Lose Fizz
    • Evidence in Favor CTC Heterogeneity Gains Strength
    • CTC Clusters Raise Research Interest
    • Detection of EMTs Gains Precedence in the Backdrop of Recent Research Findings
    • Limitations of CTC Technology for Point-of-Care Testing
    • CTC Technologies Offer an Edge over Imaging Tests for Breast Cancer Prognosis
    • Limited Biomarkers Utilized In CTC Diagnostics - A Threat to Market Growth?
    • Select Research Findings in Recent Years
    • Microfluidic Device with Micro-Hall Sensors Detect CTCs with Higher Sensitivity and Specificity
    • NBiomics Makes its Contribution to CTC Diagnosis
    • Researchers at University of Michigan Develop Revolutionary Capture CTCs Method
    • Dean Flow Fractionation to Overcome Limitations Associated with Conventional Biomarker Analysis
    • Gold Nanoparticles Help in the Detection of CTCs
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 3: World 18-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2023 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Detection & Enrichment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Detection & Enrichment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 6: World 18-Year Perspective for Detection & Enrichment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2023 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 9: World 18-Year Perspective for Analysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2023 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Direct Detection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Direct Detection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 12: World 18-Year Perspective for Direct Detection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2023 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Blood by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Blood by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 15: World 18-Year Perspective for Blood by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2023 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Bone Marrow by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Bone Marrow by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 18: World 18-Year Perspective for Bone Marrow by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2023 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Other Body Fluids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Other Body Fluids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 21: World 18-Year Perspective for Other Body Fluids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2023 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 24: World 18-Year Perspective for Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2023 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Clinical / Liquid Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 26: World Historic Review for Clinical / Liquid Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 27: World 18-Year Perspective for Clinical / Liquid Biopsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2023 & 2030
    • TABLE 28: World Circulating Tumor Cell (CTC) Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2012 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Circulating Tumor Cell (CTC) Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 31: USA 18-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Technology - Percentage Breakdown of Value Sales for Detection & Enrichment, Analysis and Direct Detection for the Years 2012, 2023 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 34: USA 18-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Application - Percentage Breakdown of Value Sales for Research and Clinical / Liquid Biopsy for the Years 2012, 2023 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 37: USA 18-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Percentage Breakdown of Value Sales for Blood, Bone Marrow and Other Body Fluids for the Years 2012, 2023 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 40: Canada 18-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Technology - Percentage Breakdown of Value Sales for Detection & Enrichment, Analysis and Direct Detection for the Years 2012, 2023 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 43: Canada 18-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Application - Percentage Breakdown of Value Sales for Research and Clinical / Liquid Biopsy for the Years 2012, 2023 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 46: Canada 18-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Percentage Breakdown of Value Sales for Blood, Bone Marrow and Other Body Fluids for the Years 2012, 2023 & 2030
  • JAPAN
    • Circulating Tumor Cell (CTC) Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 49: Japan 18-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Technology - Percentage Breakdown of Value Sales for Detection & Enrichment, Analysis and Direct Detection for the Years 2012, 2023 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 52: Japan 18-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Application - Percentage Breakdown of Value Sales for Research and Clinical / Liquid Biopsy for the Years 2012, 2023 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 55: Japan 18-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Percentage Breakdown of Value Sales for Blood, Bone Marrow and Other Body Fluids for the Years 2012, 2023 & 2030
  • CHINA
    • Circulating Tumor Cell (CTC) Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 56: China Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 58: China 18-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Technology - Percentage Breakdown of Value Sales for Detection & Enrichment, Analysis and Direct Detection for the Years 2012, 2023 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 61: China 18-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Application - Percentage Breakdown of Value Sales for Research and Clinical / Liquid Biopsy for the Years 2012, 2023 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 64: China 18-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Percentage Breakdown of Value Sales for Blood, Bone Marrow and Other Body Fluids for the Years 2012, 2023 & 2030
  • EUROPE
    • Circulating Tumor Cell (CTC) Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 67: Europe 18-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2023 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 70: Europe 18-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Technology - Percentage Breakdown of Value Sales for Detection & Enrichment, Analysis and Direct Detection for the Years 2012, 2023 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 73: Europe 18-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Application - Percentage Breakdown of Value Sales for Research and Clinical / Liquid Biopsy for the Years 2012, 2023 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 76: Europe 18-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Percentage Breakdown of Value Sales for Blood, Bone Marrow and Other Body Fluids for the Years 2012, 2023 & 2030
  • FRANCE
    • Circulating Tumor Cell (CTC) Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 77: France Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 79: France 18-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Technology - Percentage Breakdown of Value Sales for Detection & Enrichment, Analysis and Direct Detection for the Years 2012, 2023 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 82: France 18-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Application - Percentage Breakdown of Value Sales for Research and Clinical / Liquid Biopsy for the Years 2012, 2023 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 85: France 18-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Percentage Breakdown of Value Sales for Blood, Bone Marrow and Other Body Fluids for the Years 2012, 2023 & 2030
  • GERMANY
    • Circulating Tumor Cell (CTC) Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 87: Germany Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 88: Germany 18-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Technology - Percentage Breakdown of Value Sales for Detection & Enrichment, Analysis and Direct Detection for the Years 2012, 2023 & 2030
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 91: Germany 18-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Application - Percentage Breakdown of Value Sales for Research and Clinical / Liquid Biopsy for the Years 2012, 2023 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 94: Germany 18-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Percentage Breakdown of Value Sales for Blood, Bone Marrow and Other Body Fluids for the Years 2012, 2023 & 2030
  • ITALY
    • TABLE 95: Italy Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 96: Italy Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 97: Italy 18-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Technology - Percentage Breakdown of Value Sales for Detection & Enrichment, Analysis and Direct Detection for the Years 2012, 2023 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 100: Italy 18-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Application - Percentage Breakdown of Value Sales for Research and Clinical / Liquid Biopsy for the Years 2012, 2023 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 103: Italy 18-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Percentage Breakdown of Value Sales for Blood, Bone Marrow and Other Body Fluids for the Years 2012, 2023 & 2030
  • UNITED KINGDOM
    • Circulating Tumor Cell (CTC) Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 104: UK Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 105: UK Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 106: UK 18-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Technology - Percentage Breakdown of Value Sales for Detection & Enrichment, Analysis and Direct Detection for the Years 2012, 2023 & 2030
    • TABLE 107: UK Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 109: UK 18-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Application - Percentage Breakdown of Value Sales for Research and Clinical / Liquid Biopsy for the Years 2012, 2023 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 112: UK 18-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Percentage Breakdown of Value Sales for Blood, Bone Marrow and Other Body Fluids for the Years 2012, 2023 & 2030
  • REST OF EUROPE
    • TABLE 113: Rest of Europe Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 114: Rest of Europe Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 115: Rest of Europe 18-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Technology - Percentage Breakdown of Value Sales for Detection & Enrichment, Analysis and Direct Detection for the Years 2012, 2023 & 2030
    • TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 117: Rest of Europe Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 118: Rest of Europe 18-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Application - Percentage Breakdown of Value Sales for Research and Clinical / Liquid Biopsy for the Years 2012, 2023 & 2030
    • TABLE 119: Rest of Europe Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 120: Rest of Europe Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 121: Rest of Europe 18-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Percentage Breakdown of Value Sales for Blood, Bone Marrow and Other Body Fluids for the Years 2012, 2023 & 2030
  • ASIA-PACIFIC
    • Circulating Tumor Cell (CTC) Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 122: Asia-Pacific Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 123: Asia-Pacific Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 124: Asia-Pacific 18-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Technology - Percentage Breakdown of Value Sales for Detection & Enrichment, Analysis and Direct Detection for the Years 2012, 2023 & 2030
    • TABLE 125: Asia-Pacific Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 126: Asia-Pacific Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 127: Asia-Pacific 18-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Application - Percentage Breakdown of Value Sales for Research and Clinical / Liquid Biopsy for the Years 2012, 2023 & 2030
    • TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 129: Asia-Pacific Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 130: Asia-Pacific 18-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Percentage Breakdown of Value Sales for Blood, Bone Marrow and Other Body Fluids for the Years 2012, 2023 & 2030
  • REST OF WORLD
    • TABLE 131: Rest of World Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 132: Rest of World Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 133: Rest of World 18-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Technology - Percentage Breakdown of Value Sales for Detection & Enrichment, Analysis and Direct Detection for the Years 2012, 2023 & 2030
    • TABLE 134: Rest of World Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 135: Rest of World Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 136: Rest of World 18-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Application - Percentage Breakdown of Value Sales for Research and Clinical / Liquid Biopsy for the Years 2012, 2023 & 2030
    • TABLE 137: Rest of World Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 138: Rest of World Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 139: Rest of World 18-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Percentage Breakdown of Value Sales for Blood, Bone Marrow and Other Body Fluids for the Years 2012, 2023 & 2030

IV. COMPETITION